Partnerships in Clinical Trials Asia is an annual event that brings together 150+ global and regional pharma, biotech, CROs, regulators and clinical trial solution providers to network, learn, strategize and advance next practices in clinical trials in the region and forge more effective partnerships.
Clinical quality, compliance, operations and management professionals gather to discuss strategies for ensuring trial integrity by effectively assessing, optimizing and managing the quality of clinical vendors and sites.
At the Procurement and Outsourcing for Life Sciences Congress you will receive crucial information on how to identify new business needs, address major challenges in sourcing and procurement, reduce costs, maximize working capital, and more.
This October, DIA will bring together key thought leaders and experts from various fields in life sciences to explore the impact of the “global village” on local government, industry and health care providers.
Creators, innovators, storytellers and rising stars will come together at the 13th Annual Partnerships in Clinical Trials Congress, 5-6 November 2014 at the CCIB, Barcelona, Spain to provoke change and demand solutions to advancing clinical trial collaborations.
During this three-day meeting, thought leaders from around the world will provide their insight and engage in dialogue on current opportunities and challenges in managing product risk in the context of benefit.
Elite gathering of clinical professionals engage on topics critical to the effective design, development and execution of clinical trials, including risk-based monitoring, patient engagement, effective partnerships, site performance and more.
SCOPE Summit: 12 different programs, 3 Plenary Keynote Sessions, 4 New Conference, and 700+ Industry Leaders in 2015. Each conference will feature best practice case studies relevant to clinical operations experts and those new to the field.
This event will examine the drug excipients market, from the historical events that have defined the sector to the debates going on at the moment to predictions about the demands that will drive it in the future.
How did the DEG tragedies of the last century shape the regulatory landscape?
Does the sector need GMP rules?
How will the dosage forms of the future guide innovation in the excipients industry?